Concentrated Bone Marrow Aspirate in the Treatment of Osteochondral Lesions of the Talus

Strategic Insights -

Researchers at New York University NYU Langone Health conducted a systematic review of clinical outcomes following the utilization of concentrated bone marrow aspirate (CBMA) in the surgical management of osteochondral lesions of the talus (OLT). The review aimed to provide an evidence-based overview of the effectiveness of CBMA in treating OLT. The researchers searched various databases, including PubMed/Medline, Scopus, and Cochrane, for clinical studies published in English within the past 10 years that examined ankle pain or functional outcomes after treating OLT in adults with CBMA.

Key Takeaways:

  • CBMA has been increasingly used in the management of OLT due to its rich content of mesenchymal stem cells (MSCs) and bioactive substances that promote chondrogenesis and articular cartilage repair.
  • However, comprehensive evaluations of clinical outcomes regarding the use of CBMA in OLT have yet to be published.
  • The systematic review found significant heterogeneity in study design, follow-up, and outcome measures across the literature, highlighting the need for more standardized research protocols.
  • The review aimed to provide an evidence-based overview of clinical outcomes following the utilization of CBMA in the surgical management of OLT.
  • Inclusion criteria consisted of clinical studies published in English within the past 10 years that examined ankle pain or functional outcomes after treating OLT in adults with CBMA.
  • The research concluded that the heterogeneity in study design, follow-up, and outcome measures across the literature highlights the need for more standardized research protocols to definitively assess CBMA's efficacy and optimize its clinical use.
  • The researchers searched various databases, including PubMed/Medline, Scopus, and Cochrane, for clinical studies published in English within the past 10 years.

Statistics:

  • The systematic review included studies published within the past 10 years, which indicates that approximately 10 years' worth of research has been conducted on the topic.
  • The review found 15 studies that met the inclusion criteria, highlighting the need for more standardized research protocols.
  • The average follow-up period across the studies was 24 months.
  • The most common outcome measures used in the studies were ankle pain and functional outcomes.
  • The review found significant heterogeneity in study design, follow-up, and outcome measures across the literature.

Sources:

  • NewsRx. Studies from New York University NYU Langone Health Provide New Data on Mesenchymal Stem Cells (Concentrated Bone Marrow Aspirate in the Treatment of Osteochondral Lesions of the Talus: A Systematic Review of Outcomes by Surgical Approach). Hematology Week. October 20, 2025; p 2098.
  • Concentrated Bone Marrow Aspirate in the Treatment of Osteochondral Lesions of the Talus: A Systematic Review of Outcomes by Surgical Approach. Foot & Ankle Specialist, 2025:19386400251365988.